Functional Assays for Complement Regulators

  • Claire L. Harris
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 150)

Abstract

As described in Chapter 1, the complement system comprises a battery of at least 20 components capable of immediate response to a foreign organism or cell, resulting in lysis or opsonization and phagocytosis. Uncontroled complement activation would result in damage to host tissues, or in extreme cases, consumption and effective depletion of complement components. Intrinsic to the complement cascade are multiple strategies for control, such as the inherent lability of the activation enzymes, the C3 and C5 convertases, and shortlived active/binding sites, such as the binding site on C5b67 for membranes. In addition to this inherent instability, complement activation is tightly controled at multiple stages during the pathway by regulatory proteins, present both on cell membranes and in plasma (1, 2, 3, 4). The regulatory activities possessed by these proteins fall into four categories: (1) control of the active C1 complex; (2) “decay acceleration,” characterized by the ability of the regulator to “breakup” the components of the multimolecular convertase enzymes; (3) “cofactor activity,” enabling factor I to cleave and inactivate C3b or C4b; and finally, (4) inhibition of membrane attack complex (MAC) assembly. Some regulatory proteins have just one of these activities, others possess several.

Keywords

Membrane Attack Complex Hemolytic Assay Membrane Cofactor Protein Cofactor Activity Phenyl Methyl Sulfonyl Fluoride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Pensky J., Levy L., and Lepow I. (1961) Partial purification of a serum inhibitor of C1′esterase. Biol. J. Chem. 236, 1674.Google Scholar
  2. 2.
    Whaley K. and Ruddy S. (1976) Modulation of the alternative complement pathways by beta 1 H globulin. J. Experiment. Med. 144, 1147.CrossRefGoogle Scholar
  3. 3.
    Gigli I., Fujita T., and Nussenzweig V. (1979) Modulation of the classical pathway C3 convertase by the plasma proteins C4 binding protein and C3b inactivator. Proc. Natl. Acad. Sci. USA 76, 6596.PubMedCrossRefGoogle Scholar
  4. 4.
    Morgan B. P. and Meri S. (1994) Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15, 369.PubMedCrossRefGoogle Scholar
  5. 5.
    Weiler J. M., Daha M. R., Austen K. F., and Fearon D. T. (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl Acad. Sci. USA 73, 3268.PubMedCrossRefGoogle Scholar
  6. 6.
    Fearon D. T. (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc. Natl. Acad. Sci. USA 76, 5867.PubMedCrossRefGoogle Scholar
  7. 7.
    Nicholson-Weller A., Burge J., and Fearon D. T. (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129, 184.PubMedGoogle Scholar
  8. 8.
    Medof M. E., Kinoshita T., and Nussenzweig V. (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Experiment. Med. 160, 1558.CrossRefGoogle Scholar
  9. 9.
    Seya T., Holers V. M., and Atkinson J. P. (1985) Purification and functional analysis of the polymorphic variants of the C 3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J.Immunol. 135, 2661.PubMedGoogle Scholar
  10. 10.
    Brodbeck W. G., Liu D., Sperry J., Mold C., and Medof M. E. (1996) Localization of classical and alternative pathway regulatory activity within the decay accelerating factor. J. Immunol. 156, 2528.PubMedGoogle Scholar
  11. 11.
    Lublin D. M. and Coyne K. E. (1991) Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J.Experiment. Med. 174, 35.CrossRefGoogle Scholar
  12. 12.
    Oglesby T. J., Allen C. J., Liszewski M. K., White D. J., and Atkinson J. P.(1992) Membrane cofactor protein (CD46) protects cells from complement mediated attack by an intrinsic mechanism. J. Experiment. Med. 175, 1547.CrossRefGoogle Scholar
  13. 13.
    Whaley K. (1985) Measurement of complement, in Methods in Complement for Clinical Immunologists (Whaley K., ed.), Churchill Livingstone, Edinburgh, p. 77.Google Scholar
  14. 14.
    Fujita T. and Nussenzweig V. (1979) The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J. Experiment. Med. 150, 267.CrossRefGoogle Scholar
  15. 15.
    Yoon S. H. and Fearon D. T. (1985) Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J. Immunol. 134, 3332.PubMedGoogle Scholar
  16. 16.
    Seya T., Turner J. R., and Atkinson J. P. (1986) Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Experiment. Med. 163, 837.CrossRefGoogle Scholar
  17. 17.
    Seya T. and Atkinson J. P. (1989) Functional properties of membrane cofactor protein of complement. Biochem. J. 264, 581.PubMedGoogle Scholar
  18. 18.
    Gordon D. L., Kaufman R. M., Blackmore T. K., Kwong J., and Lublin D. M. (1995) Identification of complement regulatory domains in human factor H. J.Immunol. 155, 348.PubMedGoogle Scholar
  19. 19.
    Seya T., Nakamura K., Masaki T., C. Ichihara-Itoh, Matsumoto M., and Nagasawa S. (1995) Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Molec. Immunol. 32, 355.CrossRefGoogle Scholar
  20. 20.
    Adams E. M., Brown M. C., Nunge M., Krych M., and Atkinson J. P.(1991) Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J.Immunol. 147, 3005.PubMedGoogle Scholar
  21. 21.
    van den Berg C. W., J. M. Perez de la Lastra, Llanes D., and Morgan B. P. (1997) Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP). J. Immunol. 158, 1703.PubMedGoogle Scholar
  22. 22.
    Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., Matsumoto M., et al. (1998) Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells. Biochem. J. 330, 163.PubMedGoogle Scholar
  23. 23.
    Seya T., Hara T., Iwata K., Kuriyama S., Hasegawa T., Nagase Y., et al. (1995) Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients′sera. Int. Immunol. 7, 727.PubMedCrossRefGoogle Scholar
  24. 24.
    Lachmann P. J. and Thompson R. A. (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Experiment. Med. 131, 643.CrossRefGoogle Scholar
  25. 25.
    Thompson R. A. and Lachmann P. J. (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J. Experiment. Med. 131, 629.CrossRefGoogle Scholar
  26. 26.
    Whitlow M. B., Iida K., Stefanova I., Bernard A., and Nussenzweig V. (1990) H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell. Immunol. 126, 176.PubMedCrossRefGoogle Scholar
  27. 27.
    van den Berg C. W. and Morgan B. P. (1994) Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J. Immunol. 152, 4095.PubMedGoogle Scholar
  28. 28.
    Bokisch V. A., Muller-Eberhard H. J., and Cochrane C. G. (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J. Experiment. Med. 129, 1109.CrossRefGoogle Scholar
  29. 29.
    Avery V. M. and Gordon D. L. (1993) Characterization of factor H binding to human polymorphonuclear leukocytes. J. Immunol. 151, 5545.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Claire L. Harris
    • 1
  1. 1.Department of Medical BiochemistryUniversity of Wales College of MedicineCardiffUK

Personalised recommendations